Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to determine the impact of anti-checkpoint immunotherapy on type 2 inflammation via a retrospective analysis of % eosinophilia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| The study population | Patients in the University Hospitals of Montpellier system who have received anti-PD-1 and/or anti-PD-L1 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anti-PD-1 or anti-PD-L1 | Drug | Immunotherapy treatment via anti programmed death 1 and/or anti-programmed death ligand 1. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1 | Before treatment (before day 0) versus after (15 days) | |
| Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1 | Before treatment (before day 0) versus after (1 month) | |
| Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1 | Before treatment (before day 0) versus after (3 months) | |
| Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1 | Before treatment (before day 0) versus after (6 months) | |
| Change in % eosinophilia after initiation of anti-PD-1 and/or anti-PD-L1 | Before treatment (before day 0) versus after (12 months) |
| Measure | Description | Time Frame |
|---|---|---|
| Indication leading to anti-PD-1 and/or anti-PD-L1 immunotherapies | Name of pathology | Day 0 |
| Age (years) | Day 0 | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
The study population corresponds to all patients within the University Hospitals of Montpellier system who received anti-PDF-1 and/or anti-PD-L1 immunotherapies.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jeremy Charriot, MD | University Hospital, Montpellier | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| UH Montpellier | Montpellier | 34295 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sex (male/female) |
| Day 0 |